Table 1.
Baseline characteristics presented by entire cohort and by AF status
| Overall group | NSR cohort | AF cohort | p-value | |
|---|---|---|---|---|
|
n |
101 |
66 |
35 |
- |
|
Male sex |
73 (72.3%) |
48 (65.8%) |
18 (64.3%) |
1.00* |
|
Age, years |
58.9 ± 10.9 |
58.8 ± 11.1 |
59.1 ± 10.6 |
0.89 |
|
Body surface area, m
2
|
2.07 ± 0.23 |
2.04 ± 0.22 |
2.11 ± 0.26 |
0.16 |
|
Hypertension |
39 (38.6%) |
25 (37.9%) |
14 (40.0%) |
0.83* |
|
Beta blocker |
46 (45.5%) |
26 (39.4%) |
20 (57.1%) |
0.10* |
|
Digoxin |
5 (5.0%) |
2 (3.0%) |
3 (8.6%) |
0.34* |
|
Anti arrhythmic agent |
39 (38.6%) |
29 (43.9%) |
10 (28.6%) |
0.14* |
|
HR at time of CMR |
69 ± 17 |
61 ± 9 |
84 ± 20 |
<0.0001 |
|
HR range, bpm |
37-121 |
37-76 |
44-121 |
|
|
SBP, mmHg |
129 ± 16 |
132 ± 16 |
124 ± 15 |
0.02 |
|
DBP, mmHg |
73 ± 11 |
73 ± 10 |
74 ± 13 |
0.45 |
|
LVEF, % |
56.4 ± 11.1 |
59.5 ± 9.4 |
49.7 ± 11.6 |
<0.0001 |
|
LVEDVI, ml/m
2
|
76.7 ± 15.4 |
78.1 ± 15.9 |
72.7 ± 13.7 |
0.16 |
|
LVESVI, ml/m
2
|
33.5 ± 13.5 |
32.3 ± 13.7 |
37.0 ± 12.6 |
0.17 |
| LA diameter, cm | 3.9 ± 0.9 | 3.7 ± 0.7 | 4.4 ± 0.9 | 0.0001 |
*Fisher’s exact test.
[Key: SBP- systolic blood pressure; DBP- diastolic blood pressure; LVEF- left ventricular ejection fraction; LVEDVI- left ventricular end-diastolic volume indexed to body surface area; LVESVI- left ventricular end-systolic volume indexed to body surface area; LA- left atrium].